Premium
Contact immunotherapy enhances the therapeutic effects of nivolumab in treating in‐transit melanoma: Two cases reports
Author(s) -
Fujimura Taku,
Furudate Sadanori,
Kakizaki Aya,
Kambayashi Yumi,
Haga Takahiro,
Hashimoto Akira,
Aiba Setsuya
Publication year - 2016
Publication title -
the journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.9
H-Index - 65
eISSN - 1346-8138
pISSN - 0385-2407
DOI - 10.1111/1346-8138.13229
Subject(s) - nivolumab , medicine , melanoma , metastatic melanoma , immunotherapy , oncology , combination therapy , immunohistochemistry , cancer research , cancer
Because nivolumab significantly prolongs survival in patients with metastatic melanoma, enhancing its antitumor immune response is of great interest to dermato‐oncologists. In this report, we describe two cases of metastatic melanoma successfully treated with nivolumab in combination with contact immunotherapy, using contact sensitizing agents, such as squaric acid dibutylester and diphencyprone. In addition, immunohistochemical staining supported one of the possible mechanisms of this combination therapy. Our present cases suggested a possible therapy for metastatic melanoma using nivolumab in combination with contact immunotherapy.